LRRC15 targeting bispecific antibody - NovaRock Biotherapeutics
Alternative Names: Leucine rich repeat containing 15 protein targeting bispecific antibodyLatest Information Update: 05 Mar 2024
At a glance
- Originator NovaRock Biotherapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Sarcoma; Solid tumours
Most Recent Events
- 19 Feb 2024 Early research in Sarcoma in USA (Parenteral) prior to February 2024 (NovaRock Biotherapeutics pipeline, February 2024)
- 19 Feb 2024 Early research in Solid tumours in USA (Parenteral) prior to February 2024 (NovaRock Biotherapeutics pipeline, February 2024)